Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer

Overview of attention for article published in EJNMMI Research, July 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 21 Dimensions

Readers on

mendeley: 23 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 9,594 followers.

$AMAM: Lu-PSMA is highly toxic from a hematological point of view. ARX517 is clearly safer and more efficacious. https://t.co/1s93gXpjmi

22 Oct 2023

Reply Repost Favourite

As 177Lu-PSMA-617 use becomes more prevalent, important to be cognizant of this potentially dose-limiting toxicity.👇 An informative single-center series from 2021 on myelosuppression in men with #mCRPC treated with 177Lu-PSMA-617. #pcsm #OncTwitter http

31 Jan 2023

Reply Repost Favourite

New article: Hematologic safety of (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer https://t.co/23XkkbIkYV #prostatecancer #oncology https://t.co/mE7XJTIcAE

03 Jul 2021

Reply Repost Favourite